Patel Monica Arun, Vuong Samantha, Qudah Bonyan, LoConte Noelle K, Florez Narjust, Weiss Jennifer M, Ward Earlise, Hollnagel Fauzia, Matthews Michael C, Campbell Toby C
School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Support Care Cancer. 2025 Apr 26;33(5):425. doi: 10.1007/s00520-025-09491-w.
Increasing patient enrollment and promoting equity in trial participation are essential to improving cancer care outcomes. Physicians play a crucial role in decision-making, making it important to understand communication strategies used by oncologists when discussing treatment options, including clinical trial participation.
This observational qualitative study was conducted from 2022 to 2023. We recruited US medical oncologists who treat colon cancer and have access to clinical trials. Oncologists participated in simulated telehealth encounters with standardized patients with colon cancer who identified as Black or white and were referred to discuss treatment options, including a potential clinical trial.
Of 107 academic physicians contacted, 47 (44%) responded, and 21 (20%) participated. The median age was 41, 43% female, and 33% non-white. Average encounter length was 44:05 minutes. One to four treatment options were discussed. Clinical trials were discussed in nearly all conversations. Average duration of clinical trial-related talk was 08:30 minutes. Conversations with Black female patients were significantly shorter than with white female patients (mean difference: 7 minutes). Recommendations varied with 9/21 oncologists recommending a clinical trial, 9/21 deferring a decision, and 3/21 recommending standard of care. In the post-encounter survey, 86% of oncologists said they recommended a trial but only 43% actually did so.
Oncologists' communication about treatment options may impact patients' decisions and trial participation. In our study, fewer than half of oncologists recommended a trial with variability in how options were presented and the length of discussion. There was also a misperception with more oncologists thinking they recommended a trial, but they did not in the encounter. A more structured approach to these complex discussions may help oncologists communicate treatment options to patients in a more equitable and effective way.
增加患者入组并促进试验参与的公平性对于改善癌症治疗结果至关重要。医生在决策过程中起着关键作用,因此了解肿瘤学家在讨论治疗方案(包括临床试验参与)时所使用的沟通策略非常重要。
这项观察性定性研究于2022年至2023年进行。我们招募了治疗结肠癌且能够接触到临床试验的美国医学肿瘤学家。肿瘤学家参与了与被认定为黑人或白人的结肠癌标准化患者的模拟远程医疗会诊,这些患者被转介来讨论治疗方案,包括一项潜在的临床试验。
在联系的107名学术医生中,47名(44%)做出回应,21名(20%)参与。中位年龄为41岁,43%为女性,33%为非白人。平均会诊时长为44:05分钟。讨论了一至四种治疗方案。几乎在所有对话中都讨论了临床试验。与临床试验相关的谈话平均时长为08:30分钟。与黑人女性患者的对话明显短于与白人女性患者的对话(平均差异:7分钟)。建议各不相同,21名肿瘤学家中有9名推荐临床试验,9名推迟做决定,3名推荐标准治疗方案。在会诊后调查中,86%的肿瘤学家表示他们推荐了试验,但实际这样做的只有43%。
肿瘤学家关于治疗方案的沟通可能会影响患者的决策和试验参与。在我们的研究中,不到一半的肿瘤学家推荐试验,在呈现方案的方式和讨论时长方面存在差异。还存在一种误解,更多的肿瘤学家认为他们推荐了试验,但在会诊中他们并未这样做。对这些复杂讨论采用更结构化的方法可能有助于肿瘤学家以更公平、有效的方式向患者传达治疗方案。